Canopy Growth Relaunches Tweed Brand in Germany and Expands Medical Cannabis Portfolio Following MTL Acquisition
Canopy Growth Corporation has announced a major strategic milestone in its international expansion strategy with the relaunch of its Tweed brand in the German medical cannabis market, alongside the introduction of three newly developed cannabis strains from MTL Cannabis Corp., a wholly owned subsidiary of the Company. The announcement marks Canopy Growth’s first international product rollout following its acquisition of MTL and reflects a renewed focus on strengthening its presence in high-growth global medical cannabis markets.
The dual initiative underscores Canopy Growth’s ambition to leverage its legacy brand equity while integrating enhanced cultivation capabilities and premium genetics to meet increasing demand from physicians and patients in Europe’s largest medical cannabis market.
Strengthening Presence in Germany’s Expanding Medical Cannabis Market
Germany has emerged as one of the fastest-growing medical cannabis markets in the world, driven by increasing patient access, evolving regulatory frameworks, and rising physician acceptance of cannabis-based therapies. The market is projected to approach nearly $1 billion in annual value by 2025, reflecting significant growth potential for established and emerging cannabis companies alike.
Against this backdrop, Canopy Growth’s decision to relaunch the Tweed brand in Germany represents a strategic effort to capture a larger share of the expanding market while reinforcing its position as a trusted provider of medical cannabis products.
The Tweed brand, one of the most recognized names in the global cannabis industry, has historically been associated with quality, consistency, and standardized production practices. By reintroducing Tweed into the German medical market, Canopy Growth aims to reestablish strong brand recognition among healthcare professionals and patients while aligning its offerings with the country’s strict medical regulatory environment.
The relaunch also reflects Canopy Growth’s broader European strategy, as the company continues to identify the European Union as a key long-term growth region for medical cannabis expansion.
MTL Acquisition Enhances Product Quality and Supply Capabilities
A central component of the company’s expansion strategy is the integration of MTL Cannabis Corp., a wholly owned subsidiary known for its premium cannabis genetics and cultivation expertise. The acquisition has significantly strengthened Canopy Growth’s ability to develop and supply high-quality cannabis products for both domestic and international markets.
MTL’s genetic development capabilities are now being leveraged to power the relaunch of the Tweed brand in Germany, ensuring that newly introduced products meet stringent quality and consistency standards required in medical cannabis markets.
The integration of MTL also enhances Canopy Growth’s production capacity at a time when demand for medical cannabis products is increasing rapidly across Europe. By combining established brand equity with advanced cultivation techniques, the company aims to improve its competitiveness in key international markets.
New Strains Introduced Under Tweed Brand
As part of the German relaunch, Canopy Growth has introduced three cannabis cultivars developed by MTL Cannabis Corp. These strains—Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes—have been selected for their consistent quality, genetic stability, and suitability for medical use.
Each strain has been developed with a focus on delivering reliable therapeutic characteristics, an essential factor in medical cannabis prescribing practices where consistency and predictability are critical for patient care. The introduction of these cultivars represents the first phase of a broader product rollout strategy under the refreshed Tweed brand.
Canopy Growth has indicated that additional MTL-derived strains are expected to be launched in June 2026, with up to five new cultivars planned for introduction. The company also anticipates further portfolio expansion throughout the year, signaling a sustained commitment to product diversification and market growth.
Leadership Highlights Strategic Importance of European Expansion
Canopy Growth’s leadership emphasized the importance of the German launch as a foundational step in the company’s broader European expansion strategy.
Luc Mongeau, Chief Executive Officer of Canopy Growth, described Germany as one of the fastest-growing and most strategically important medical cannabis markets globally. He noted that demand continues to increase rapidly as more physicians integrate cannabis-based treatments into patient care and as regulatory frameworks evolve to support broader access.
Mongeau highlighted that the relaunch of the Tweed brand represents a significant milestone for the company, reflecting both its historical brand strength and its renewed commitment to delivering high-quality medical cannabis products to international markets.
He also emphasized that the acquisition of MTL has strengthened Canopy Growth’s ability to meet rising demand while enhancing its product development capabilities. According to Mongeau, the European Union represents a substantial long-term opportunity for the company, with Germany serving as the initial entry point for expanded regional growth.
Expanding Medical Cannabis Acceptance in Europe
The European medical cannabis landscape has undergone rapid transformation in recent years, with countries such as Germany leading the way in regulatory reform and patient access expansion. Germany’s established reimbursement pathways for medical cannabis and increasing physician familiarity with cannabinoid-based treatments have contributed to steady market growth.
As awareness of cannabis-based therapies continues to rise, pharmaceutical and cannabis companies are increasingly investing in product standardization, clinical research, and supply chain infrastructure to support long-term market development.
Canopy Growth’s entry strategy in Germany aligns with these trends, focusing on delivering standardized, pharmaceutical-grade cannabis products that meet strict medical requirements. The relaunch of the Tweed brand is intended to reinforce trust among healthcare providers while ensuring consistency across product offerings.
Integration of Branding and Cultivation Strategy
The integration of Tweed branding with MTL’s cultivation expertise represents a key strategic alignment within Canopy Growth’s broader business model. By combining a well-established consumer-facing brand with advanced genetic development capabilities, the company aims to strengthen its position in both established and emerging cannabis markets.
This approach allows Canopy Growth to differentiate its products through both brand recognition and scientific consistency, which are increasingly important factors in the competitive medical cannabis industry.
The company’s focus on controlled cultivation environments, genetic stability, and product standardization is designed to support physician confidence and improve patient outcomes through reliable dosing and predictable therapeutic effects.
Regulatory and Financial Disclosure Update
Alongside its product and market expansion announcement, Canopy Growth also disclosed a regulatory development involving the issuance of a management cease trade order (MCTO). The order was granted by the Ontario Securities Commission, the company’s principal regulator, under National Policy 12-203.
The MCTO became effective on May 28, 2026, and relates to previously announced non-cash accounting adjustments involving technical errors in financial reporting. These errors are connected to certain share-settled warrants denominated in U.S. dollars, originally issued during the fiscal year ending March 31, 2024.
The company previously disclosed the issue on May 15, 2026, and stated its intention to restate and refile affected financial statements. The corrected financial statements will be included in the company’s Annual Report on Form 10-K for the fiscal year ending March 31, 2026.
Canopy Growth expects to file the comprehensive Form 10-K with both Canadian securities regulators and the U.S. Securities and Exchange Commission by June 15, 2026. The company has indicated that the refiling process is intended to ensure full compliance with regulatory requirements and maintain transparency with investors.
Strategic Outlook for International Growth
Despite near-term regulatory and reporting considerations, Canopy Growth continues to focus on expanding its global medical cannabis footprint. The relaunch of the Tweed brand in Germany represents an important step in rebuilding international momentum and strengthening the company’s position in one of the world’s most promising cannabis markets.
By combining established brand equity, enhanced production capabilities through MTL, and a growing product pipeline, Canopy Growth is positioning itself to compete more effectively in the evolving global medical cannabis industry.
As demand for medical cannabis continues to rise in Europe and other international markets, the company’s strategy of integrating premium genetics with trusted branding may play a central role in its long-term growth trajectory.
The German launch, supported by upcoming product expansions and continued investment in cultivation innovation, signals Canopy Growth’s intent to remain a key player in the global medical cannabis sector while capitalizing on the rapid evolution of patient access and regulatory acceptance worldwide.
About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.
Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.
